Bright Minds Biosciences Inc.
DRUG
CNSX
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 34.86% | 13.03% | -14.46% | -35.42% | -29.56% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 143.64% | 0.10% | -61.83% | -63.97% | -61.01% |
Operating Income | -143.64% | -0.10% | 61.83% | 63.97% | 61.01% |
Income Before Tax | -141.33% | 38.24% | 84.50% | 62.55% | 60.02% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -141.33% | 38.24% | 84.50% | 62.55% | 60.02% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -141.33% | 38.24% | 84.50% | 62.55% | 60.02% |
EBIT | -143.64% | -0.10% | 61.83% | 63.97% | 61.01% |
EBITDA | -- | -- | -- | -- | -- |
EPS Basic | -38.43% | 63.11% | 86.67% | 65.79% | 65.67% |
Normalized Basic EPS | -38.41% | 63.14% | 86.69% | 65.80% | 65.67% |
EPS Diluted | -38.07% | 62.97% | 86.43% | 65.52% | 65.55% |
Normalized Diluted EPS | -38.48% | 63.09% | 86.65% | 65.80% | 65.67% |
Average Basic Shares Outstanding | 49.69% | 39.69% | 28.95% | 15.59% | 18.86% |
Average Diluted Shares Outstanding | 52.57% | 42.70% | 32.09% | 15.59% | 18.86% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |